Dapagliflozin
Brand: Farxiga (US/EU) / Forxiga (EU) / Dapa (IN/BD)
Antidiabetic
SGLT2 inhibitor
Pharmacokinetics
| Half-life | 12 hours |
| Tmax | 2 h |
| Bioavailability | 78 % (approx) |
| Protein Binding | 91 % |
| Volume of Distribution | 1.5 L/kg (approx) |
| Clearance Route | mixed |
| Active Metabolites | no |
| Notes | Initiation thresholds vary by indication; follow local HF/CKD guidance. |
⚠️ Safety & Warnings
Severity: Moderate
Adverse Effects:
Genital mycotic infections, polyuria, volume depletion, rare euglycemic DKA
Contraindications:
Dialysis
Precautions:
Teach sick-day rules; pause before surgery/acute illness; monitor volume status and ketones when unwell